TRIALS IN TREATING STIs, VACCINES AND LIPID LOWERING MEDICATIONS
Dr Pi Lip Seet,
Principal Investigator
Paratus Clinical, Brisbane &
Surgical Registrar
Brisbane, Queensland, Australia
RESEARCHER PROFILE
Filmed in Brisbane | March 2026
Dr Pi Lip Seet graduated from the University of Queensland with a Bachelor of Medicine and Bachelor of Surgery, after completing a Bachelor of Biomedical Science at the University of Newcastle. He has undertaken broad hospital-based training across Queensland and the ACT, with clinical experience in Emergency Medicine, General and Orthopaedic Surgery, Plastic and Reconstructive Surgery, Intensive Care and Coronary Care.
Since joining Paratus Clinical Research in 2022, Dr Seet has served as both Principal Investigator and Sub-Investigator across Phase I–IV industry-sponsored clinical trials. His research experience spans vaccines, immunology, cardiovascular and endocrine disease, respiratory medicine, gastroenterology, pain management, sleep medicine and adult psychiatry. He has been involved in multiple vaccine development programs, including RSV, influenza, COVID-19, herpes zoster and pneumococcal studies.
Dr Seet maintains current Good Clinical Practice certification and advanced life support training. With a strong foundation in acute and procedural medicine, he is committed to delivering high-quality, ethical clinical research, ensuring participant safety while supporting the advancement of innovative therapeutic and vaccine programs.
Source: Supplied
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Elite athlete physical and mental health impact performance
Understanding the interaction between genes and lifestyle factors in response to stress can lead to potential therapeutic interventions for stress-related disorders. This research is crucial for promoting health and well-being.
Professor Mehta has recently commenced research into elite athlete physical and mental health impact performance, with research at the intersection of statistics, genomics, and mental health. This research is ahead of, and in anticipation of, the Summer Olympics in Brisbane in 2032.
-
Next-generation NK cell-based immunotherapies for hard-to-treat cancers
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
